2023-07-05 12:00:24
Ruhr University Bochum (RUB) has joined a Europe-wide joint project called CLAIMS, which aims to utilize artificial intelligence (AI) for the treatment of multiple sclerosis (MS). The project has received a funding of almost ten million euros from the European Commission as part of the Innovative Health Initiative (IHI). It includes 15 partners from nine different countries.
MS is an autoimmune disease of the central nervous system that affects a large number of patients in the EU and Germany. According to the German Multiple Sclerosis Society (dmsg), there are around 700,000 MS patients in the EU and over 280,000 in Germany. The disease is currently incurable and characterized by phases.
The main objective of the CLAIMS project is to establish a data pool comprising findings from radiology, clinical neurology, and laboratory results in a visualized form. This will provide doctors with quick access to personalized treatment perspectives based on data-driven precision medicine. The project is expected to run for four years and is considered prestigious in the field.
Prof. Carsten Lukas, senior physician at the Institute for Neuroradiology in the St. Josef Hospital, represents RUB in the project. He emphasizes the importance of magnetic resonance imaging (MRI) in the treatment of MS. By linking MRI with various clinical data and laboratory findings, the value of MRI in the diagnosis and treatment of MS will increase significantly.
MS is a disease with varying symptoms and characteristics, leading to its nickname “the disease of 1000 faces.” With the CLAIMS project, RUB and its partners aim to use a new, sophisticated database to tailor therapies precisely to the individual needs of MS patients.
The consortium has notable expertise in AI-based image analysis and forecast modeling for MS. The project is coordinated by the Charité in Berlin, and other clinical partners include the CHU University Hospital in Lille, Casa di Cura Igea in Milan, the General University Hospital in Prague, and the Technical University of Dresden. Pharmaceutical companies Bristol-Myers Squibb and Hoffmann-La Roche are also involved on the industrial side.
The integration of AI into the field of medicine, specifically in the treatment of diseases like MS, holds significant promise for improved patient care and outcomes. The precision and personalized therapy enabled by the CLAIMS project could revolutionize the way MS is diagnosed and treated, bringing hope to the millions of patients affected by the disease.]
#patients #hope #artificial #intelligence